Security key
005329107
Adagene Inc. - Ordinary shares, par value USD $0.0001 per share (ADAG)
CUSIP: 005329107
Q3 2025 13F Holders as of 30 Sep 2025
- Security type / class
- Equity / Ordinary shares, par value USD $0.0001 per share
- Total 13F shares
- 5,722,260
- Total 13F value
- $11,251,842
- Share change
- -344,072
- SEC-reported price per share
- $1.99
- Number of holders
- 17
- Value change
- -$681,939
- Number of buys
- 5
- Number of sells
- 5
- Shares outstanding
- 83,843,205
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q3 2025
Institutions
17
Top holders
10
ADAG full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q4 2025
Adagene Inc. SEC filings
Adagene Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 005329107
Recent filing periods:
Ownership snapshot
Top reported holders of ADAG - Adagene Inc. - Ordinary shares, par value USD $0.0001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
WuXi PharmaTech Healthcar...
Disclosed value leader
WuXi PharmaTech Healthcar...
Comparable rows
15/15
Latest evidence
30 Sep 2025
13D/G
13F
Lead comparable stake: 7%
13D/G row: WuXi PharmaTech Healthcare Fund I L.P.
Showing 1-6 of 15 holder rows.
Quick read
WuXi PharmaTech Healthcare Fund I L.P. leads the comparable SEC ownership view at 7%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens WuXi PharmaTech Healthcare Fund I L.P.'s linked filing trail.
Comparable ownership
Top 5
WuXi PharmaTech Healthcare Fund I...
7%
Panacea Innovation Ltd
3.8%
FIL Ltd
1.8%
FMR LLC
0.9%
GENERAL ATLANTIC, L.P.
4.6%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| WuXi PharmaTech Healthcare Fund I L.P. |
13D/G
|
7%
|
$8,187,161
4,121,815 shares
|
-$1,701,888 | 30 Sep 2025 |
| Panacea Innovation Ltd |
13D/G
Panacea Venture Healthcare Fund II, L.P.
|
3.8%
|
$4,469,175
2,250,000 shares
|
-$1,564,211 | 30 Sep 2025 |
| FIL Ltd |
13D/G
FIL Limited
|
1.8%
|
$1,320,902
936,810 shares
|
-$4,450,930 | 31 Mar 2025 |
| FMR LLC |
13D/G
13F
Company
|
0.9%
|
$933,679
473,949 shares
|
$0 | 30 Jun 2025 |
| GENERAL ATLANTIC, L.P. |
13F
Company
|
4.6%
|
$7,460,606
3,825,952 shares
|
— | 30 Jun 2025 |
| HSG Holding Ltd |
13F
Company
|
1.6%
|
$2,619,560
1,343,364 shares
|
— | 30 Jun 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q3 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
17
Shares
5,722,260
Rows available
17
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q3 2025 vs Q1 2026 Across Filers
Q1 2026 holders
24
Q3 2025 holders
17
Holder diff
-7
| Investor | Q1 2026 Shares | Q3 2025 Shares | Share Diff | Share Chg % | Q1 2026 value | Q3 2025 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend